SUPPLEMENTARY DATA

APPENDIX – The DiMe Study Group is composed of the following members:

Principal investigators: Hans K. Åkerblom, JaakkoTuomilehto

Coordinators: Raisa Lounamaa, Liisa Toivonen

Data management: Esa Virtala, Janne Pitkäniemi

Local investigators: Anders Fagerlund, Marina von Flittner, Brage Gustafsson, Christer Häggquist, Alpo Hakulinen, Liisa Herva, Pertti Hiltunen, Ture Huhtamäki, Niilo-Pekka Huttunen, Tuula Huupponen, Teuvo Joki, Ritva Jokisalo, Marja-Liisa Kär, Seppo Kallio, Eero A. Kaprio, Ulla Kaski, Mikael Knip, Leena Laine, Juhani Lappalainen, Jorma Mäenpää, Anna-Liisa Mäkelä, Kyrö Niemi, Anja Niiranen, Anja Nuuja, Pekka Ojajärvi, Timo Otonkoski, Kaisa Pihlajamäki, Seppo Pöntynen, Jukka Rajantie, Juhani Sankala, Jörgen Schumacher, Matti Sillanpää, Marja-Riitta Ståhlberg, Carl-Henrik Stråhlmann, Tapani Uotila, Markus Väre, Pertti Varimo, Gunilla Wetterstrand.

Special investigators: Antti Aro, Merja Hiltunen, Helena Hurme, Heikki Hyöty, Jorma Ilonen, Jukka Karjalainen, Mikael Knip, Pauli Leinikki, Aaro Miettinen, Tuula Petäys, Leena Räsänen, Helena Reijonen, Antti Reunanen, Tero Saukkonen, Erkki Savilahti, Eva Tuomilehto-Wolf, Paula Vähäsalo, Suvi. M. Virtanen.

©2015 American Diabetes Association. Published online at http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc15-1027/-/DC1

SUPPLEMENTARY DATA

This appendix has been provided by the authors to give readers additional information about their work

Supplement to: Juusola M, Parkkola A, Härkönen T, Siljander H, Ilonen J, Åkerblom HK, Knip M, and the Childhood Diabetes in Finland Study Group: Positivity for Zinc Transporter 8 Autoantibodies at Diagnosis Is Subsequently Associated with Reduced β-Cell Function and Higher Exogenous Insulin Requirement in Children and Adolescents with Type 1 Diabetes

Supplementary Table 1. Frequencies (%) of autoantibody combinations in 723 children with newly diagnosed type 1 diabetes.

	All patients	Patients grouped by age			Statistics
	n=723	I. < 5 yrs (n=147)	II. 5-9.9 yrs (n=286)	III. 10-14.99 yrs (n=290)	*P*
ZnT8+	73.3	62.6	74.8	77.2	0.004
ZnT8+,GADA-	14.5	12.2	18.2	12.1	0.078
ZnT8+,IA-2A-	6.9	4.8	7.0	7.9	0.466
ZnT8+,ICA-	6.5	0.7	3.5	12.4	<0.001
ZnT8+,IAA-	35.1	10.9	9.2	43.4	<0.001
No detectable antibodies	1.2	0.0	1.4	1.7	0.294
One antibody positive	4.1	4.8	2.8	5.2	0.330
Only ZnT8+	0.6	0.0	0.30	1.0	0.324
Two antibodies positive	3.2	1.4	2.8	4.5	0.191
ZnT8+,GADA+	1.0	0.0	0.0	2.4	0.005
ZnT8+,IA-2A+	1.2	0.0	1.0	2.1	0.170
ZnT8+,ICA+	0.7	0.7	1.4	0.0	0.129
ZnT8+,IAA+	0.3	0.7	0.3	0.0	0.421
Three antibodies positive	21.0	14.3	25.2	20.3	0.029
ZnT8+,GADA+,ICA+	3.0	2.7	4.2	2.1	0.321
ZnT8+,GADA+,IAA+	0.4	1.4	0.0	0.3	0.110
ZnT8+,GADA+,IA-2A+	1.9	0.0	1.4	3.4	0.033
ZnT8+,ICA+,IAA+	0.3	0.0	0.3	0.3	0.774
ZnT8+,ICA+,IA-2A+	6.2	3.4	8.4	5.5	0.102
ZnT8+,IAA+,IA-2A+	0.1	0.0	0.0	0.3	0.474
Four antibodies positive	32.2	27.2	33.2	33.8	0.342
ZnT8+,GADA+,ICA+,IAA+	1.1	3.4	0.3	0.7	0.011
ZnT8+,GADA+,ICA+,IA-2A+	20.9	6.8	22.4	26.6	<0.001
ZnT8+,ICA+,IAA+,IA-2A+	5.1	7.5	6.3	2.8	0.054
ZnT8+,GADA+,IAA+,IA-2A	1.0	0.0	0.3	2.1	0.044
All five antibodies positive	29.9	40.1	28.0	26.6	0.009
Multiple (at least two) antibodies positive	94.6	95.2	95.8	93.1	0.332

©2015 American Diabetes Association. Published online at http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc15-1027/-/DC1